Daily Medication Pearl: Fluticasone Furoate and Vilanterol (Breo Ellipta)

Breo Ellipta is indicated for long-term, once-daily, maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease.

Medication Pearl of the Day: Fluticasone Furoate and Vilanterol (Breo Ellipta)

Indication: Breo Ellipta is a combination of fluticasone furoate, an inhaled corticosteroid, and vilanterol, a long-acting beta2-adrenergic agonist, indicated for long-term, once-daily, maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease.

Insight:

  • Dosing: Inhalation of Breo Ellipta 100/25 once daily.
  • Dosage forms: Inhaler containing 2 foil blister strips of powder formulation for oral inhalation. One strip contains fluticasone furoate 100 or 200 mcg per blister and the other contains vilanterol 25 mcg per blister.
  • Adverse events: Nasopharyngitis, upper respiratory tract infection, headache, oral candidiasis, back pain, pneumonia, bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, hypertension, influenza, pharyngitis, and pyrexia.
  • Mechanism of action: Fluticasone furoate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Vilanterol is a long-acting Beta agonist.
  • Manufacturer: GlaxoSmithKline

Sources: